Jesse Fishman

Jesse Fishman is an associate in Goodwin’s Business Law department and a member of its Technology and Life Sciences groups and a member of the Capital Markets practice. Jesse represents public and private companies in the pharmaceutical, biotechnology, and medical device industries and advises clients in a variety of corporate matters, including start-up and formation matters, venture capital financings, initial public offerings, de-SPACs and capital markets transactions, strategic investments, and other general corporate matters.

• Represented Kymera Therapeutics, Inc. in its $275 million follow-on offering
• Represented Scholar Rock Holding Corporation in its $100 million at-the-market offering
• Represented Scholar Rock Holding Corporation in its $205 million follow-on offering
• Represented Scholar Rock Holding Corporation in its $85 million follow-on offering
• Represented BridgeBio Pharma, Inc. in its $250 million follow-on offering
• Represented BridgeBio Pharma, Inc. in its $450 million ATM facility
• Represented Senti Biosciences, Inc. in its business combination with Dynamics Special Purpose Corp.
• Represented Senti Biosciences, Inc. in its $50 million ChEF Purchase Agreement with Chardan Capital Markets LLC
• Represented Titan Partners Group in a $20 million Registered Direct Offering of Aileron Therapeutics, Inc.
• Represented Chardan Capital Markets in its $25 million ChEF Purchase Agreement with Sonnet BioTherapeutics Holdings, Inc.
• Represented C3is Inc. in its $6 million follow-on offering of common stock and warrants
• Represented C3is Inc. in its $7 million follow-on offering of common stock and warrants
• Represented Jefferies LLC in Calliditas Therapeutics’ $75 million at-the-market offering of American Depositary Shares
• Represented Jefferies LLC in Silence Therapeutics’ $100 million at-the-market offering of Ordinary Shares
• Represented Jefferies LLC in Alpha Tau Medical’s $75 million at-the-market offering of Ordinary Shares
• Represented Jefferies LLC in Alpha Tau Medical’s $150 million at-the-market offering of Common Shares
• Represented the underwriters in a secondary follow-on public offerings of Privia Health Group shares
• Represented the underwriters in Silence Therapeutics $56 million follow-on offering
• Represented the placement agents in a $2.1 million registered direct offering of Presto Automation
• Represented the placement agent in a $1.2 million registered direct offering of Presto Automation
• Represented HOOKipa Pharma in connection with a $35 million equity investment by a strategic partner
• Represented Precipio Inc. in its $2 million registered direct offering and concurrent PIPE
• Represented Precipio Inc. in its ATM facility with AGP
• Represented NanoDx in is $11 million convertible note offering
• Represented NanoDx in its Series D financing
• Represented AI Proteins in its Series Seed financing
• Represented Axcella Health in its $25 million registered direct offering
• Regularly assists clients in private placements of debt and equity securities
• Represented a Nasdaq listed biometric technology company in secured debt financings
• Represented a Nasdaq listed biometric technology company in follow on offering of common stock and warrants
• Represented a Nasdaq listed biometric technology company in registration of securities underlying its employee stock purchase plan and equity and incentive plan
• Represented an electric vehicle charging company in connection with its uplist to the Nasdaq Capital Market and closing of its underwritten public offering
• Represented an intelligent technology solutions company in connection with a private placement capital raise
• Represented a Nasdaq listed biosciences company in connection with a follow on public offering of its common stock and warrants
• Represented a placement agent in connection with a registered direct offering of common stock
• Represented a private artificial intelligence company in the sale of its assets to a publicly traded company
• Represented a closely held company in its investment into a toy production company
• Represented a vertically integrated cannabis company in connection with its sale of an option to purchase common stock to a global cannabinoid company

Prior to joining Goodwin in 2021, Jesse was an associate in the Princeton, New Jersey office of Fox Rothschild LLP and an associate in the New Jersey office for Lucosky Brookman LLP.

Jesse is a member of the New Jersey State Bar Association and the New York State Bar Association.

In law school, Jesse was the Vice President of the Moot Court Board, received the Deborah Sloyer Memorial Scholarship which is awarded to a graduating student who demonstrates excellence in trial and appellate advocacy courses, and was the Symposium Editor and Alumni Affairs Coordinator of the Hofstra Labor & Employment Law Journal. Jesse also received the Gold Level Pro Bono Award for over 500 hours of pro bono legal work.

• "Risk Factor Considerations In The Time Of COVID-19," June 2020
• "SEC And States Provide Relief For Upcoming Proxy Season Due To COVID-19," April 2020
• "Delaware General Corporation Law Updates Tackle COVID-19, Proxy Information And Emergency Provisions," July 2020
• "What to Disclose and When: SEC Corporate Filings in the Time of COVID-19," July 2020